Abstract
Objectives
To assess the concurrent validity and responsiveness of the Health Utility Index 3 (HUI3) in patients with advanced HIV/AIDS, and to determine the responsiveness of this measure, the MOS-HIV and EQ-5D to HIV-related clinical events.
Methods
Data from the OPTIMA (OPTions In Management with Antiretrovirals) trial was analyzed. Two aspects of the validity of the HUI3 were considered: concurrent validity was evaluated using Spearman correlations with MOS-HIV component and summary scores. Responsiveness to AIDS-defining events (ADE) and all adverse events (our external change criterion) was assessed using area under the receiver operating characteristic (AUROC) curves.
Results
The study enrolled 368 patients (mean follow-up: 3.66 years); 82% had at least one severe adverse event and 27% had at least one ADE. The HUI3 scale and items showed good concurrent validity, with 85% of the expected relationships with the MOS-HIV subscales verified. The HUI3 was responsive to both adverse events (AUROC [95%CI]: 0.68 [0.57, 0.80]) and ADEs (0.62 [0.51, 0.74]). The EQ-5D was responsive to ADEs (0.66 [0.56, 0.76]), but not responsive to adverse events (0.56 [0.46, 0.68]).
Conclusion
The HUI3 is a valid and responsive measure of the change in HRQoL associated with clinical events in an advanced HIV/AIDS population.
Similar content being viewed by others
Abbreviations
- ARV:
-
Antiretroviral
- AE:
-
Adverse events
- HIV:
-
Human immunodeficiency virus
- AIDS:
-
Acquired immune deficiency syndrome
- AUROC:
-
Area under the receiver operating characteristic curve
- MHS:
-
Mental health score
- PHS:
-
Physical health score
References
Torres, R. A., & Barr, M. (1997). Impact of combination therapy for HIV infection on inpatient census. New England Journal of Medicine, 336, 1531–1532.
Hirschel, B., & Francioli, P. (1998). Progress and problems in the fight against AIDS. New England Journal of Medicine, 338, 906–908.
Crothers, K., Butt, A. A., Gilbert, C. L., Rodriguez-Barradas, M. C., Crystal, S., Justice, A. C., et al. (2006). Increased COPD among HIV-positive compared to HIV-negative veterans. Chest, 130(5), 1326–1333.
Tsiodras, S., Mantzoros, C., Hammer, S., & Samore, M. (2000). Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Archives of Internal Medicine, 160, 2050–2056.
Kamin, D. S., & Grinspoon, S. K. (2005). Cardiovascular disease in HIV-positive patients. AIDS, 19, 641–652.
Tsasis, P. (2000). Health-related quality of life measurements in HIV/AIDS care. AIDS Patient Care STDs, 14(8), 427–438.
Kyriakides, T. C., Babiker, A., Singer, J., Cameron, W., Schechter, M. T., Holodniy, M., et al. (2003). An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: Rationale and design of the OPTIMA trial. Controlled Clinical Trials, 24, 481–500.
Neumann, P. J., Goldie, S. J., & Weinstein, M. C. (2000). Preference-based measures in economic evaluation in health care. Annual Review of Public Health, 21, 587–611.
Guyatt, G. H., King, D. R., Feeny, D. H., Stubbing, D., & Goldstein, R. S. (1999). Generic and specific measurement of health related quality of life in a clinical trial of respiratory rehabilitation. Journal of Clinical Epidemiology, 52(3), 187–192.
Wu, A. W., Jacobson, D. L., Frick, K. D., Clark, R., Revicki, D. A., Freedberg, K. A., et al. (2002). Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Quality of Life Research, 11, 273–282.
Anis, A. H., Nosyk, B., Sun, H., Guh, D. P., Bansback, N., Li, X., & Optima Team (2009). Quality of life of patients with advanced HIV/AIDS: Measuring the impact of both AIDS defining events and non-AIDS serious adverse events. Journal of Acquired Immune Deficiency Syndrome (in press).
Clayson, D. J., Wild, D. J., Quarterman, P., Duprat-Lomon, I., Kubin, M., & Coons, S. J. (2006). A comparative review of health-related quality of life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics, 24(8), 751–765.
Chan, K. S., & Revicki, D. A. (1998). Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients with the human immunodeficiency virus. Evaluation & Health Professions, 21(2), 265–281.
Lubeck, D. P., & Fries, J. F. (1992). Changes in quality of life among persons with HIV infection. Quality of Life Research, 1(6), 359–366.
Carretero, M. D., Burgess, A. P., Soler, P., Soler, M., & Catalan, J. (1996). Reliability and validity of an HIV-specific health-related quality of life measure for use with injection drug users. AIDS, 10, 1699–1705.
Paton, N. I., Chapman, C. A., Chan, S. P., Tan, K. M., Leo, Y. S., Aboulhad, J., et al. (2002). Validation of the medical outcomes study HIV health survey as a measure of quality of life in HIV-infected patients in Singapore. International Journal of STDs and AIDS, 13, 456–461.
Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997). Evidence for reliability, validity and usefulness of the medical outcomes study HIV health survey (MOS-HIV). Quality of Life Research, 6, 481–493.
Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72.
Coons, S. J., Rao, S., Keininger, D. L., & Hays, R. D. (2000). A comparative review of generic quality-of-life instruments. Pharmacoeconomics, 17, 13–35.
Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.
Torrance, G. W., Furlong, W., Feeny, D., & Boyle, M. (1995). Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics, 7(6), 503–520.
Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.
Boyle, M. H., Furlong, W., Feeny, D., Torrance, G. W., & Hatcher, J. (1995). Reliability of the Health Utilities Index—mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Quality of Life Research, 4(3), 249–257.
Horsman, J., Furlong, W., Feeny, D., & Torrance, G. (2003). The Health Utilities Index (HUI®): Concepts, measurement properties and applications. Health & Quality of Life Outcomes, 1, 54.
Bayoumi, A. M., & Redelmeier, D. A. (1999). Economic methods for measuring the quality of life associated with HIV infection. Quality of Life Research, 8, 471–480.
Fayers, P. M., & Machin, D. (2006). Quality of life. The assessment, analysis and interpretation of patient-reported outcomes (2nd ed.). West Sussex: Wiley.
Common Terminology Criteria for Adverse Events, Version 3.0. https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome_to_ctcae.htm. Accessed Jan 2009.
Sackett, D. L., Haynes, R. B., Tugwell, P. (1985). The interpretation of diagnostic data. In Clinical epidemiology: A basic science for clinical medicine (pp. 59–138). Boston: Little, Brown.
DeLong, E. R. (1988). Comparing the areas under tow or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics, 44, 837–845.
Terwee, C. B., Bot, S. D. M., de Boer, M. R., van der Windt, D. A. W. M., Knol, D. L., Dekker, J., et al. (2007). Quality criteria were proposed for measurement properties of heath status questionnaires. Journal of Clinical Epidemiology, 60, 34–42.
Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Medical Care, 33, AS173–AS182.
Hays, R. D., & Hadorn, D. (1992). Responsiveness to change: An aspect of validity, not a separate dimension. Quality of Life Research, 1(1), 73–75.
Patrick, D. L., & Chiang, Y. P. (2000). Measurement of health outcomes in treatment effectiveness evaluations: Conceptual and methodological challenges. Medical Care, 38(9 Suppl), II14–II25.
Streiner, D. L., & Norman, G. R. (2008). Health measurement scales: A practical guide to their development and use (4th ed.). New York: Oxford University Press Inc.
Terwee, C. B., Dekker, F. W., Wiersinga, W. M., Prummel, M. F., & Bossuyt, P. M. M. (2003). On assessing responsiveness of health-related quality of life instruments: Guidelines for instrument evaluation. Quality of Life Research, 12, 349–362.
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61, 102–109.
Aiken, L. R. (1977). Note on sensitivity: A neglected psychometric concept. Perceptual and motor skills, 45, 1330.
Krabbe, P. F. M., Peerenboom, L., Langenhoff, B. S., & Ruers, T. J. M. (2004). Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Quality of Life Research, 13, 1247–1253.
Husted, J. A., Cook, R. J., Farewell, V. T., & Gladman, D. D. (2000). Methods for assessing responsiveness: A critical review and recommendations. Journal of Clinical Epidemiology, 53, 459–468.
Acknowledgments
The OPTIMA study was funded by the Canadian Institutes of Health Research (Canada), Cooperative Studies Program of the US Department of Veterans Affairs Veterans Health Administration (USA), and the Office of Research and Development, Cooperative Studies Program, United Kingdom Medical Research Council. BN was supported by doctoral research awards from the Michael Smith Foundation for Health Research, the Canadian Institutes of Health Research, and the Research in Addictions and Mental Health Policy & Services CIHR strategic training initiative.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nosyk, B., Sun, H., Bansback, N. et al. The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Qual Life Res 18, 815–824 (2009). https://doi.org/10.1007/s11136-009-9504-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-009-9504-0